Filing Flows › Xenetic Biosciences (XBIO) › Q4 2025
Xenetic Biosciences (XBIO) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Mar 12, 2026
Xenetic Biosciences (XBIO) reported revenue of $766K for the fourth quarter 2025 (Q4 2025), +18% from a year earlier and -25% from the quarter before. Operating margin was -81.3%, net loss $579K (75.6% of revenue).
Xenetic Biosciences, Q4 2025: revenue $766K (+18% year over year), operating margin -81.3%, net loss $579K, operating cash flow −$243K. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $766K | -25% | +18% |
| Operating profit | −$623K | — | — |
| Net earnings | −$579K | — | — |
| Operating cash flow | −$243K | — | — |
What changed
Revenue was $766K in Q4 2025, up 18% year over year and down 25% from the previous quarter.
Operating costs exceeded revenue by $623K, an operating margin of -81.3%. Total costs fell 21% while revenue rose 18%. The quarter ended with a net loss of $579K, wider than the previous quarter's $510K loss.
Operating cash flow was −$243K. Non-cash charges added back $14K of share-based compensation. Working capital and other items added $322K.
Questions
What was Xenetic Biosciences' revenue in the fourth quarter 2025?
Xenetic Biosciences (XBIO) reported revenue of $766K for the fourth quarter 2025 (Q4 2025), +18% from a year earlier and -25% from the quarter before.
Was Xenetic Biosciences profitable in the fourth quarter 2025?
Operating loss was $623K (-81.3% of revenue) and net loss $579K.